# Dyne Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Dyne Therapeutics, Inc.).

## Overview

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted therapies for genetically driven neuromuscular diseases. Its FORCE platform is designed to deliver therapeutic payloads to muscle tissue and the central nervous system using TfR1-mediated delivery, with programs focused on Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy, and Pompe disease.

## Products & services

• FORCE platform for TfR1-mediated tissue delivery
• DYNE-101 for myotonic dystrophy type 1 (DM1)
• DYNE-251 for Duchenne muscular dystrophy (DMD)
• DYNE-302 for facioscapulohumeral dystrophy (FSHD)
• DYNE-401 for Pompe disease
• Preclinical pipeline in CNS and muscle diseases

- **Clinical-stage product candidates** (0%) — Lead therapeutic programs in DM1, DMD, FSHD and Pompe disease advancing through preclinical and clinical development.
- **FORCE platform technology** (100%) — A modular delivery platform that uses TfR1 targeting to transport oligonucleotides, enzymes and other payloads to muscle and CNS.
- **Preclinical pipeline expansion** (0%) — Earlier-stage programs for CNS, rare skeletal muscle, cardiac and metabolic muscle diseases.

- FORCE platform for TfR1-mediated tissue delivery
- DYNE-101 for myotonic dystrophy type 1 (DM1)
- DYNE-251 for Duchenne muscular dystrophy (DMD)
- DYNE-302 for facioscapulohumeral dystrophy (FSHD)
- DYNE-401 for Pompe disease
- Preclinical pipeline in CNS and muscle diseases

## Customers

Dyne does not yet sell approved products, so its near-term customers are not patients but regulators, clinical investigators, trial sites, and future commercial payers. If approved, its end customers would be patients with rare neuromuscular diseases and the physicians who treat them, with reimbursement decisions heavily influenced by specialty payers.

- **Rare neuromuscular disease patients** (primary) — Patients with genetically driven muscle diseases who would use Dyne's therapies if approved, seeking functional improvement and disease modification.
- **Specialist physicians** (primary) — Neurologists, neuromuscular specialists and metabolic disease physicians who diagnose, prescribe and monitor treatment.
- **Payers and reimbursement authorities** (primary) — CMS, private insurers and utilization management groups that decide coverage and access for high-cost specialty drugs.
- **Clinical research ecosystem** (secondary) — Trial sites, CROs and investigators that execute preclinical and clinical development programs.
- **Potential commercial partners** (secondary) — Biopharma partners that could support development, licensing or commercialization in selected indications.

- Patients with rare neuromuscular diseases such as DM1, DMD, FSHD and Pompe
- Neuromuscular specialists and treating physicians who prescribe rare-disease therapies
- Clinical trial sites and investigators running Phase 1/2 studies
- Payers and reimbursement bodies that determine access after approval
- Potential future partners or licensees for collaboration and commercialization

## Geography

Dyne is headquartered in the United States and operates as a U.S.-based clinical-stage biotech with global commercial rights to its programs. The company has not disclosed country-level revenue because it has not generated product revenue, and its business is currently concentrated in U.S.-based research, clinical development and regulatory activities.

- Headquartered in the United States
- Clinical development and corporate operations are primarily U.S.-based
- Global commercial rights to all programs
- No product revenue disclosed yet, so no country revenue mix
- Future commercialization may require international clinical and regulatory reach

## Strategy

Dyne's strategy is to use its FORCE platform to build a portfolio of differentiated therapies for genetically defined neuromuscular diseases with clear regulatory paths and high unmet need. Near term, the company is focused on advancing clinical programs, expanding the platform into additional muscle and CNS indications, and preserving access to capital until it can reach commercialization or partnership milestones.

- **Advance lead clinical programs** (short-term) — Clinical proof-of-concept is the main value driver for a pre-revenue biotech and de-risks the platform.
- **Expand FORCE platform applications** (medium-term) — A broader platform can create multiple shots on goal and improve partnering optionality.
- **Secure capital and optional partnerships** (short-term) — The company expects continued losses and needs funding to sustain R&D and commercialization readiness.

- Advance DM1, DMD, FSHD and Pompe programs through clinical development
- Use FORCE modularity to deploy different payload classes and mechanisms
- Expand into CNS, skeletal muscle, cardiac and metabolic muscle diseases
- Build data packages with clear translational and regulatory pathways
- Maintain funding through equity, debt and collaboration options

## Risks

Dyne is a pre-revenue biotech with significant operating losses, so its business depends on successful clinical development, regulatory approval and access to capital. It also relies heavily on third-party CROs, CMOs and other vendors, while facing intense competition from other rare-disease and delivery-platform developers.

- **Clinical development failure** [high] — Lead programs are still in early stages, and efficacy or safety issues could halt or delay approval.
- **Capital dilution or financing shortfall** [high] — The company expects continued losses and will need external funding before product revenue begins.
- **Third-party manufacturing and trial execution** [medium] — Clinical and manufacturing operations depend on external vendors that can disrupt timelines or raise costs.
- **Competitive displacement** [medium] — Other companies may develop better or earlier therapies for the same rare diseases or delivery problem.
- **Reimbursement and market access** [medium] — Even approved rare-disease therapies can face restrictive coverage and utilization management.

- No approved products and no product revenue yet
- Need for substantial additional capital to fund development
- Clinical trial and regulatory failure risk across multiple programs
- Dependence on third-party CROs, CMOs and service providers
- Intense competition from gene therapy, gene editing and other delivery platforms

## Accounting

The most important accounting judgments are accrued research and development expenses and stock-based compensation, both of which can materially affect reported losses as clinical activity scales. Because Dyne has no product revenue, investors should also watch how management accounts for capital raises, collaboration payments if any, and the timing of R&D vendor accruals that can shift quarterly results.

- **Accrued research and development expenses** — Can materially shift quarterly operating loss and accrued liabilities
- **Stock-based compensation** — Impacts operating expenses and net loss without affecting cash burn
- **Future collaboration and milestone revenue** — Could create lumpy revenue recognition if partnerships are signed

- Accrued R&D expenses depend on estimates for CRO and CMO work performed
- Stock-based compensation is a major non-cash expense for a biotech workforce
- No product revenue yet, so future revenue recognition will be event-driven
- Quarterly losses can swing with clinical trial timing and vendor accruals
- Future collaboration or milestone accounting could affect reported revenue

---

*Last updated: 2026-04-28T20:02:32.595376+00:00*